Real-time quantitative reverse transcription-PCR assay for renal cell carcinoma-associated antigen G250

Clinica Chimica Acta

Volumn 318, Issue 1-2, 2002, Pages 33-40

  Chuanzhong, Ye ^a,b   Ming, Guan ^c   Fanglin, Zhang ^d   Haijiao, Chen ^a   Zhen, Lin ^b   Shiping, Chen ^b   Yongkang, Zhang ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

G250; MRNA; Real time quantitative RT PCR; Renal neoplasm

Indexed keywords

MESSENGER RNA; TUMOR ANTIGEN; TUMOR MARKER;

ACCURACY; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CELL PROLIFERATION; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; GENE THERAPY; HUMAN; HUMAN TISSUE; KIDNEY; KIDNEY CARCINOMA; MUTATION; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DNA PRIMERS; DNA, COMPLEMENTARY; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; QUALITY CONTROL; REFERENCE STANDARDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0036190570     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00799-9     Document Type: Article

References (12)

1. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250
2. Blood-based RT-PCR assays of MN/CA9 or PSMA: Clinical application in renal cancer patients
3. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
4. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
5. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers
6. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays
7. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes
8. Real-time quantitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t(8;21)-positive acute myelogenous leukemia
9. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney
10. Quantitative analysis of TEL/AML1 fusion transcripts by real-time RT-PCR assay in childhood acute lymphoblastic leukemia
11. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications
12. The presence of a pseudogene may affect the use of HPRT as an endogenous mRNA control in RT-PCR